TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00664014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tablet;15mg/tab;15/30/60mg/day for 7days Plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
Study: NCT02203903

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor associated antigen lymphocytes (TAA-T)
Description: TAA-T may be generated from donors or recipients and will be tested for specificity to 3 tumor antigens commonly found in hematological malignancies (WT1, PRAME, and SURVIVIN,). The goal of this cell infusion will be to initiate an immune response to residual leukemia or lymphoma that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).
Study: NCT04904705

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach
Description: The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach is a cognitive-based approach. This is a person-oriented, performance-solving problem-solving approach that enables strategy acquisition and guided exploration for the acquisition and learning of new skills.~The main objectives of this approach are; define and transfer domain-specific strategies to other motor-based tasks to gain skills, learn problem-solving strategy (goal, plan, do, check) and adapt to other environments (such as home, school).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Program
Description: Home Program are activities that a participant can apply at home to improve their skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Program
Description: Home Program are activities that a participant can apply at home to improve their skills.
Study: NCT00711386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK706769
Description: 50mg, 100mg, 200mg, or 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK706769
Description: 50mg, 100mg, 200mg, or 400mg
Study: NCT02053805

Intervention type: OTHER
Group type: OTHER
Intervention: urine flow and residual
Description: The post void residual will be recorded by using ultrasound. Creatinine level will be checked.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: a multiparametric prostate MRI
Description: The MRI will be reported on a 5 point Likert Scale

Intervention type: PROCEDURE
Group type: OTHER
Intervention: trans-rectal ultra-sound guided prostate biopsy
Description: 12 core Trans-rectal prostatic biopsy for diagnostic purposes
Study: NCT03451448

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MRI
Description: PET/MRI with USPIO contrast

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MRI
Description: PET/MRI with USPIO contrast

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI with USPIO contrast
Study: NCT01907685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE8062
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Pharmaceutical form: solution for infusion~Route of administration: Intravenous
Study: NCT03034941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg twice per day per os for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg twice per day per os for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide + metformin
Description: In the COMBI group the initial dose of metformin was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg twice per day. Liraglutide 1.2 mg once per day s.c. was added after first two weeks of monotherapy with metformin.
Study: NCT03455387

Intervention type: DIAGNOSTIC_TEST
Intervention: sampling of the serum marker sFlt1 and PlGF
Description: sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
Study: NCT01818349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isokinetic lower-limb training
Description: concentric training of the affected plantarflexors, hip flexors and hip extensors
Study: NCT00711386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK706769
Description: 50mg, 100mg, 200mg, or 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK706769
Description: 50mg, 100mg, 200mg, or 400mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03501147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 15 minutes of resistance training during work every day
Study: NCT02095054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle.~Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Symptom questionnaire completed at each study visit.
Study: NCT04226248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine Transdermal System
Description: Rivastigmine Trandermal Patches applied once a day for up to 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transdermal System
Description: Placebo Trandermal Patches applied once a day for up to 12 months
Study: NCT01004341

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Family-based behavioral weight control intervention
Description: Standard behavioral weight control program for children ages 8-12 years old and their parents in a family-based intervention.
Study: NCT05385640

Intervention type: OTHER
Intervention: NO intervention
Description: NO intervention

Intervention type: OTHER
Intervention: NO intervention
Description: NO intervention
Study: NCT03598595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO
Study: NCT00836576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril HCl 40 mg Tablets
Description: 1 x 40 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotensin® 40 mg Tablets
Description: 1 x 40 mg, single-dose fasting
Study: NCT01880632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Patients will be given the perioperative chemotherapy as below once recruited:~Capecitabine ：500 mg tablets（Roche） Oxaliplatin：50mg/10ml（according to daily practice in each center）~Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
Study: NCT02807597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301
Description: -LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301
Description: -LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301
Description: -LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301
Description: -LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301
Description: -LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer Vision Goggles and standard fluorescence imaging systems
Description: -Member of the operating team will wear the CVG during surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer Vision Goggles and standard fluorescence imaging systems
Description: -Member of the operating team will wear the CVG during surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer Vision Goggles and standard fluorescence imaging systems
Description: -Member of the operating team will wear the CVG during surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer Vision Goggles and standard fluorescence imaging systems
Description: -Member of the operating team will wear the CVG during surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer Vision Goggles and standard fluorescence imaging systems
Description: -Member of the operating team will wear the CVG during surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: -Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: -Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: -Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: -Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: -Standard of care
Study: NCT01959672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4-Dimensional Computed Tomography
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir Mesylate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study: NCT02000362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cells
Study: NCT02374385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPSC-1001 (VSVΔG-ZEBOV)
Description: Ebola vaccine candidate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPSC-1001 (VSVΔG-ZEBOV)
Description: Ebola vaccine candidate
Study: NCT01818349

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: isokinetic upper-limb training
Description: concentric training of the affected wrist extensors, elbow flexors and shoulder flexors
Study: NCT02568904

Intervention type: OTHER
Intervention: Alcohol
Description: every participant will drink vodka at a dose of 2ml/kg bodyweight

Intervention type: OTHER
Intervention: Glucose
Description: oral Glucose tolerance test

Intervention type: OTHER
Intervention: Fructose
Description: oral fructose tolerance test

Intervention type: OTHER
Intervention: vehicle
Description: control (water)
Study: NCT03633331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03146312

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MVM/phytochemical supplement
Description: Consumption of an MVM/phytochemical supplement for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
Study: NCT02090543

Intervention type: DRUG
Intervention: Phenprocoumon (Marcumar)
Description: common use, no requirements (real life situation)

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY-59 7939)
Description: common use, no requirements (real life situation)
Study: NCT01009294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Oral powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronic Corticosteroid Therapy
Description: Enrollment was stratified to ensure evaluation of approximately half of the participants were receiving chronic corticosteroid therapy and approximately half of participants were not receiving chronic corticosteroid therapy. Therefore, 3 out of 6 participants were receiving chronic corticosteriod therapy. For the participants receiving chronic corticosteriod therapy, a stable corticosteriod regimen was to be maintained during the study.
Study: NCT04655625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A (AG0302-COVID19)
Description: 2 mg of AG0302-COVID19 twice at 2-week intervals

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Group A (Placebo)
Description: Placebo twice at 2-week intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B (AG0302-COVID19)
Description: 2 mg of AG0302-COVID19 twice at 4-week intervals

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Group B (Placebo)
Description: Placebo twice at 4-week intervals
Study: NCT03671122

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac imaging in the PREFERS and CABG PREFERS cohorts
Description: performed at baseline and after 1 year

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac imaging in the PREFERS and CABG PREFERS cohorts
Description: performed at baseline and after 1 year

Intervention type: OTHER
Intervention: Biomarker analysis in the PREFERS and CABG PREFERS chorts
Description: blood samples will be taken for biomarker analysis at baseline and after 1 year

Intervention type: OTHER
Intervention: Biomarker analysis in the PREFERS and CABG PREFERS chorts
Description: blood samples will be taken for biomarker analysis at baseline and after 1 year

Intervention type: PROCEDURE
Intervention: Cardiac biopsies in the CABG PREFERS cohort
Description: myocardial biopsies from the right trium the left and right ventricles will be taken during elective CABG
Study: NCT04537442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM21 CAR-T cells
Description: IM21 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days~Other Names:~Fludarabine Cyclophosphamide
Study: NCT00373074

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Blood Patch
Description: Use 15 cc of blood

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Blood Patch
Description: Inject 20 cc of blood into epidural space

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Blood Patch
Description: Inject 30 cc of autologous blood
Study: NCT00587223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apligraf
Description: Up to 3 applications: Day 0, Month 1, Month 2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dressing regimen
Description: Dressing regimen will be comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer
Study: NCT02511210

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: regional anesthesia
Description: preoperative anxiety

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: preoperative anxiety
Study: NCT04205552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML Intravenous Solution
Description: Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min
Study: NCT00614393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: IV infusion
Study: NCT02374385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPSC-1001 (VSVΔG-ZEBOV)
Description: Ebola vaccine candidate
Study: NCT00614393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: IV infusion
Study: NCT03071744

Intervention type: DRUG
Group type: OTHER
Intervention: Lazanda
Description: Lazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution.
Study: NCT03639389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil
Study: NCT02374385

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT03388671

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAB Block
Description: patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided TAB Block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Psoas Block
Description: patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block or TAB block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block or TAB block
Study: NCT02646124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500mg by mouth two times a day, #20

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg by mouth two times a day, #20

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 28 placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28
Study: NCT03639389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesics
Description: Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients
Study: NCT01588509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study: NCT04075578

Intervention type: DRUG
Intervention: OnabotulinumtoxinA / Botox®, Allergan Ltd, Irvine, CA, United-States
Description: Botox® intradetrusor injections, with a rigid cystoscope, under local anaesthesia performed by Lidocaïne 2% diluted in 30ml of bicarbonate 14‰. 20 injections of 0,5ml each will be heterogeneously administrated into the bladder wall, sparing the trigone
Study: NCT02561585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 124249

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT03092466

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: femoral nerve catheter
Description: femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral nerve catheter
Description: femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: femoral group
Description: femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
Study: NCT03092466

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: infusion of saline solution (15ml) in femoral catheter